Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1655 • ACR Convergence 2022
Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
Eline J. Arends¹, Mihaela Zlei², Christopher M. Tipton³, Jasna Cotic⁴, Zgjim Osmani¹, Fenna J. De Bie², Sylvia W.A. Kamerling¹, Andre Van Maurik⁵, Richard Dimelow⁶, Yun Irene Gregan⁷, Norma Lynn Fox⁸, Ton J. Rabelink¹, David A. Roth⁹, Iñaki Sanz¹⁰, Jacques J.M. Van Dongen², Cees Van Kooten¹ and Onno Teng¹¹, ¹Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Immunology, Leiden University Medical Center, Leiden, Netherlands, ³Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Clinical Biomarker Group, Stevenage, United Kingdom, ⁷GlaxoSmithKline, Clinical Science Immunology, Collegeville, PA, ⁸GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ⁹GlaxoSmithKline, Research and Development, Collegeville, PA, ¹⁰Emory University, Atlanta, GA, ¹¹Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients (pts) with active…
Abstract Number: 2029 • ACR Convergence 2022
Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
Liselotte Deroo¹, Helena Achten², Kristel De Boeck², Eva Genbrugge², Wouter Bauters², Dimitri Roels², Frederick Dochy², David Creytens², Filip Van den bosch³, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁴Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁵Ghent University Hospital, Ghent, Belgium
Background/Purpose: Presence of anti-SSA/Ro antibodies is one of the 2016 ACR-EULAR classification criteria for primary Sjögren's Syndrome (pSS). Anti-SSA/Ro antibodies comprise reactivity against Ro52 and/or…
Abstract Number: 0333 • ACR Convergence 2022
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…
Abstract Number: 0770 • ACR Convergence 2022
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
Amarah Baluch¹, Katerina Warda², Taylor Middleton², Kiersten Kennedy², Andras Perl³ and Jihad Ben Gabr¹, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical Unviersity, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Immune check point inhibitors (ICIs) boost the patient's immune system by blocking intrinsic down-regulators of immunity by signaling through cytotoxic T-lymphocyte antigen 4 (CTLA-4),…
Abstract Number: 1201 • ACR Convergence 2022
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
Emily G Oakes¹, Jack Ellrodt¹, Roberta Alexander², John Conklin², May Choi³, Hongshu Guan¹, Sara Tedeschi¹, Jeffrey Sparks⁴, Siobhan Case⁵, Tiffany Hsu¹, Daniel Solomon¹, Anna Jonsson¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Exagen, Inc., Vista, CA, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA
Background/Purpose: Onset of autoimmune connective tissue disease (CTD) after COVID-19 infection has been reported and complement activation has been implicated. We examined common autoimmune rheumatic…
Abstract Number: 1658 • ACR Convergence 2022
Association Between Anti-Sjögren Syndrome/Scleroderma Autoantigen 1 (SSSCA1) Antibodies and Cancer in Systemic Sclerosis
Rachel Wallwork¹, Livia Casciola-Rosen¹ and Ami Shah², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: We sought to examine the association between anti-Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) antibody and cancer in systemic sclerosis (SSc). We also describe the frequency…
Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Jonathan Hubbard¹, Kim Campbell¹, Kathy Sivils¹, Robert Hoffman¹, Kim Hung Lo¹, Jocelyn Leu¹, Sophia Liva¹, Qing Zuraw¹, Anne Stevens¹, Leona Ling², Keith Karcher³, Sindhu Ramchandren³, Hong Sun³, Hal Scofield⁴, Daniel Wallace⁵ and Raphaèle Seror⁶, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Cambridge, MA, ³Janssen Research & Development, LLC, Titusville, NJ, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
Abstract Number: 0337 • ACR Convergence 2022
Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
Rebecca Wood¹, Catriona Wagner², Carla J. Guthridge³, Joel Guthridge³, Steve Wallace⁴, Pennina R Safer⁵ and Judith James³, ¹Oklahoma Medical Research Foundation, Edmond, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Immunarray, Richmond, ⁵Immunarray, Rehovot, Israel
Background/Purpose: Incomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for SLE classification. While a subset of ILE patients transition to…
Abstract Number: 0788 • ACR Convergence 2022
Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study
Tal Gazitt¹, Jacqueline Shear², Joy Feld³, Amir Haddad⁴, Muna Elias⁵, Nizar Hijazi⁶, Idit Lavi¹, Tali Eviatar⁷, Victoria Furer⁸, Hagit Peleg⁹, Ori Elkayam¹⁰ and Devy Zisman¹, ¹Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Carmel Medical Centre, Haifa, Israel, ⁵Carmel Medical Center, Rheumatology Unit, Haifa, Israel, ⁶Carmel medical centre1Carmel Medical Center, Rheumatology Unit, Haifa, Israel, ⁷Tel Aviv Sourasky medical center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Hadassah Medical Center, Jerusalem, Israel, ¹⁰Tel Aviv Medical Center, Rheumatology, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: Little is known regarding autoantibody generation and clinically manifest autoimmunity following BNT162b2 mRNA vaccination. Our objective was to investigate the development of autoantibodies following…
Abstract Number: 1278 • ACR Convergence 2022
ANA Testing Practices in the United States: A Population-Based Study Between 2000 and 2019
Mehmet Hocaoglu¹, Alain Sanchez-Rodriguez², Hannah Langenfeld³, Cynthia Crowson⁴ and Ali Duarte-Garcia⁵, ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵Mayo Clinic, Rochester, MN
Background/Purpose: Inappropriate laboratory testing accounts for an important part of avoidable healthcare costs. Anti-nuclear antibody (ANA) is a commonly used laboratory test in rheumatology with…
Abstract Number: 1685 • ACR Convergence 2022
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Alexandra Taylor¹, Michael Duryee², Carlos Hunter², nozima Aripova², Ted Mikuls³ and Geoffrey Thiele², ¹Creighton University School of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
Abstract Number: 2033 • ACR Convergence 2022
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 0450 • ACR Convergence 2022
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Enrico Brunetta¹, Giacomo Ramponi², marco folci², Maria De Santis³, Giacomo Maria Guidelli¹, Angela Ceribelli⁴, Nicoletta Luciano¹, Marta Caprioli⁵, Arianna Sonaglia¹ and Carlo Selmi⁶, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Internal Medicine, Rozzano, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy
Background/Purpose: Serum antineutrophil cytoplasmic antibodies (ANCA) are significantly associated with the development of ANCA-associated vasculitides (AAV) but may also be detected in patients with other…
Abstract Number: 0795 • ACR Convergence 2022
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
Neel Thanavala¹, Kiho Son², Nardien Sedhom², Snehal Somalwar³, Zil Patel¹, Rameen Jamil², Carmen Venegas², Ashutosh Thakar², Agnes Yuen⁴, Melanie Kjarsgaard², Susan Waserman², Mylinh Duong², Parameswaran Nair², Christopher Carlsten⁴, Maggie Larche², Terence Ho², Sarah Svenningsen², KONSTANTINOS TSELIOS⁵ and Manali Mukherjee², ¹The Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Post-Acute Sequalae of COVID-19 (PASC), prevalent in ~20-30% of convalescent COVID-19 patients is characterized by new/persistent symptoms after the initial recovery. Certain autoantibodies have…
Abstract Number: 1379 • ACR Convergence 2022
Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)
Nicholas Gold¹, Fangming Liao¹, JingJing Cao¹, Daniela Dominguez¹, Andrea Knight², Deborah Levy³ and Linda Hiraki⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease capable of affecting multiple organ systems. Genetic variants in the Human Leukocyte Antigen (HLA) are associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].